Health
Ando Foundation and Nissin Food Products Release "Recipes for Wellbeing Report": First Global Study Reveals Direct Correlation Between Food and Wellbeing
OSAKA, Japan, Oct. 18, 2023 /PRNewswire/ -- The Ando Foundation (*) (hereinafter "the Foundation") and Nissin Food Products Co., Ltd. (hereinafter "the Company") released the Recipes for Wellbeing Report onOctober 18, 2023, in cooperation with global analytics and advice firm Gallup, the first gl...
2023-10-18 16:00
1744
WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong
* Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain inHong Kong. * HKSTP Park companies will leverage WuXi...
2023-10-18 11:00
1513
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
SUZHOU, China and ROCKVILLE, Md., Oct. 17, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the registrational Phase III study (HQP1351AG...
2023-10-18 10:11
1469
Ubie's new Generative AI feature for doctors effortlessly summarizes patient findings and streamlines medical record documentation with a 90% User Satisfaction rate.
NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Ubie
2023-10-17 23:00
1896
Congratulations to Sanyou Bio for achieving ISO9001 & IPMS certifications
SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd is pleased to announce inOctober 2023, we have obtained ISO 9001 and IPMS certifications. These certifications emphasize Sanyou's commitment to consistency, reliability, and accountability in our innovative biopharmaceuti...
2023-10-17 21:00
1488
Global Healthcare Startup Sky Labs Attracts Investments Totaling KRW 20.7 Billion in a Series C Round
- Major investors include Korea Development Bank (KDB), K2 Investment Partners, DEVSISTERS VENTURES, SJG Partners, and OPENWATER INVESTMENT - Distribution of 'CART BP,' a ring-type cuffless blood pressure monitor that enables continuous blood pressure measurement and monitoring 24/7, will be ful...
2023-10-17 20:00
1606
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality
* WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly improve productivity and quality, and reduce cost-of-goods (COGS) in commercial manufacturin...
2023-10-17 08:30
1598
CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announ...
2023-10-17 08:00
9913
Chamlion Partners with GPAINNOVA to Accelerate the Digitization of Dental Industry
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- On October 15th, Chamlion and global surface metal finishing expert GPAINNOVA signed a strategic cooperation agreement. Chamlion will become GPAINNOVA's exclusive dental strategic partner inChina. The two companies will establish a joint venture in China to...
2023-10-16 22:27
1479
Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology（ESMO）
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib（ABSK011）and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with...
2023-10-16 21:50
1742
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeut...
2023-10-16 21:10
1566
TaiMed Announces Significant Progress in Clinical Trials for New HIV Treatment
Company champions long-acting HIV therapy with new biologic drug TMB-365/380
combination; after favorable results of Phase1b/2a, company plans to accelerate
Phase 2 clincial study to expedite path to market
TAIPEI, Oct. 16, 2023 /PRNewswire/ -- TaiMed Biologics
2023-10-16 21:00
1434
SeekIn Presents New Validation Studies of OncoSeek Multi-cancer Early Detection test at Early Detection of Cancer Conference in London
Two Sample Types, Three Different Platforms, Five Independent Cohorts of ~10,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict Tissue of Origin of Cancers SHENZHEN, China, Oct. 16, 2023 /PRNewswi...
2023-10-16 20:00
1433
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapie...
2023-10-16 20:00
1727
Abbisko presented two preclinical research results at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko" hereafter) announced that the results of the company's two preclinical studies published at the 35th International Molecular Targets and Cancer Treatment Conference (EORTC) be held inBoston, U.S.. These two research...
2023-10-16 18:20
1531
CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China
BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK),a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease and rare oncology, ...
2023-10-16 13:38
1385
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL
SUZHOU, China, and ROCKVILLE, Md., Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has entered into a clinical collaboration ...
2023-10-16 09:23
2017
Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023
HONG KONG, Oct. 14, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, the "Group", HKEX stock code: 0460) is pleased to announce that the "Group" was selected as one of the first echelon of enterprises in The ...
2023-10-14 20:09
2854
Nona Biosciences and INGENIA Therapeutics Enter into Collaboration Agreement
CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and INGENIA Therapeutics, a preclinical-stage biotech company with a breakthrough technology to restore defective blood vessels, announced ...
2023-10-13 23:26
2678
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
* IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile * IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD) * An interim data readout in AA is expected in Q3 20...
2023-10-13 20:00
2018
Week's Top Stories
Most Reposted
Mastercard goes OTP-free in APAC for faster, safer online transactions
[Picked up by 326 media titles]
2024-11-06 09:00Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
[Picked up by 319 media titles]
2024-11-07 09:00
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 309 media titles]
2024-11-12 09:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 284 media titles]
2024-11-12 11:00
Most Read
Mastercard goes OTP-free in APAC for faster, safer online transactions
2024-11-06 09:00
13117
Brankas Launches Integrated APAC Open Banking Compliance Solution with ADVANCE.AI's eKYC Solution
2024-11-07 09:00
10117
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
2024-11-07 11:34
7458
XTEP's First Mono Store in Malaysia Comes to Puchong
2024-11-07 10:08
6173
